EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance

Akie Yoshinaga, Kohdai Kitamoto, Shuichiro Aoki iD, Ryo Terao iD, Tatsuya Inoue, Ryo Obata, Keiko Azuma iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326018 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Akie Yoshinaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Antibodies, Monoclonal, Humanized, Angiogenesis Inhibitors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To identify predictors of extension of the injection interval beyond 8 weeks at the 24-month visit after switching to brolucizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV).

Design

Retrospective observational study Methods 17 eyes of 16 patients with persistent or recurrent exudation on aflibercept were switched to intravitreal brolucizumab and managed with a treat-and-extend (T&E) regimen with a minimum 8-week interval after loading. The primary outcome contrasted extension (>8 weeks) versus non-extension (≤8 weeks) at month 24. Prespecified predictors were early central choroidal thickness (CCT) change from baseline to the switch visit (A0 to A1; ≥ 40% reduction) and pachychoroid. Associations were tested with Fisher’s exact tests and Firth-penalized logistic regression with the event defined as extension.

Results

At 24 months, 6 of 17 eyes (35%) achieved extension. A ≥ 40% early CCT reduction occurred in 0 of 6 extension eyes versus 7 of 11 non-extension eyes (Fisher exact two-sided P ≈ 0.035). In the Firth model (event = extension), < 40% CCT reduction strongly predicted extension (odds ratio 38.5; profile-likelihood 95% CI 2.0–10,000; LR P = 0.004). Non-pachychoroid showed the same direction with wide CIs (odds ratio 14.3; 95% CI 0.99–2,174; LR P = 0.006). Model fit was significant (LR χ² = 15.19, P = 0.0005) and discrimination was good (apparent AUC ≈ 0.97). We prespecified a parsimonious two-predictor model to limit overfitting; adding age, sex, prior photodynamic therapy, or number of prior aflibercept injections did not materially change coefficients or improve AICc (ΔAICc < 2).

Conclusions

Eyes without marked early choroidal thinning (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAntibodies, Monoclonal, HumanizedAngiogenesis InhibitorsChoroidal NeovascularizationChoroid DiseasesHumansMaleFemaleAgedRetrospective StudiesDrug ResistanceMiddle AgedIntravitreal InjectionsTreatment OutcomeChoroidAged, 80 and overPolypoidal Choroidal Vasculopathy

Substanzen

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsafliberceptbrolucizumabAntibodies, Monoclonal, HumanizedAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
  • Department of Ophthalmology and Showa General Hospital, Hanakoganei, Kodaira, Tokyo, Japan.
  • Department of Ophthalmology and Micro-Technology, Yokohama City University School of Medicine, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, Japan.
  • Department of Ophthalmology and Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, Japan.

ORCID-Profile: Shuichiro Aoki, Ryo Terao, Keiko Azuma

Zitieren

APA

Yoshinaga, A., Kitamoto, K., Aoki, S., Terao, R., Inoue, T., Obata, R., & Azuma, K. (2025). Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance. PLOS One. https://doi.org/10.1371/journal.pone.0326018

Vancouver

Yoshinaga A, Kitamoto K, Aoki S, Terao R, Inoue T, Obata R, et al. Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance. PLOS One. 2025. doi:10.1371/journal.pone.0326018

BibTeX
@article{Yoshinaga2025,
  author = {Yoshinaga, Akie and Kitamoto, Kohdai and Aoki, Shuichiro and Terao, Ryo and Inoue, Tatsuya and Obata, Ryo and Azuma, Keiko},
  title = {Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326018}
}
Kostenlos starten →